Herpesviruses can enter host cells by pH-dependent endocytic pathways in a cell-specific manner. The role of pH in herpesvirus endocytosis is unclear. Herpes simplex virus (HSV) is a paradigm for virus membrane fusion via a complex of glycoproteins. HSV glycoproteins B, D and the heterodimer H-L are necessary and sufficient for membrane fusion. This work analyzes the structure and function of HSV glycoproteins B, D, and H-L at neutral pH, and at the physiological low-pH encountered during endocytic entry. It is demonstrated that mildly acidic low pH triggers specific conformational changes in HSV gB at a pH of 5.7 to 6.0. The antigenic structure of gB functional region I that is critical for fusion is specifically altered by mildly acidic pH both in vitro and during entry into host cells. Point mutations within gB functional region 1 that block membrane fusion still allow conformational changes in region 1. This suggests that specific hydrophobic residues are essential for fusion domain insertion into the host cell membrane but not conformational change. The detected conformational changes were reversible, similar to other class III fusion glycoproteins. Exposure to mildly acidic pH directly triggered the fusion function of HSV glycoproteins and caused gB, but not other glycoproteins, to become more hydrophobic. The oligomeric conformation of gB is altered at a similar pH range. In addition, several approaches were used to monitor gB throughout glycoprotein synthesis and maturation. It is shown that gB may cotranslationally fold and oligomerize as it is synthesized on the ribosome. As gB matures it then alters conformation and/or binding partner to form antigenically distinct populations of gB within the cell and virion. I conclude that intracellular low pH induces changes in gB conformation that, together with additional triggers such as receptor-binding, are essential for virion-cell fusion during herpesviral entry by endocytosis.

Le Virus de l’Hépatite C (VHC) infecte 170 millions de personnes dans le monde mais aucun vaccin n’est encore disponible. Le processus d’entrée du VHC dans les hépatocytes représente une cible prometteuse pour le développement de stratégie thérapeutique et est finement régulé par un nombre par les deux glycoprotéines d’envelope du VHC, E1 et E2, assemblé sous la forme d’un hétérodimère incorporé à la surface des particules virales. Cependant, comment E1 et E2 dialoguent, modifient leurs conformations et se coordonnent mutuellement au cours de l’entrée reste encore à être définit. Dans ce travail, nous avons souhaité clarifier l’interrelation entre E1 and E2 au cours de l’entrée afin d’ouvrir la voie à de potentiels stratégies thérapeutiques. Nous avons tout d’abord examiné si une importante divergence génétique entre des hétérodimères E1E2 pouvait être liée à l’existence de fonctions particulières. Nous avons observé une spécialisation des E1E2 isolé des Lymphocytes B pour l’infection de ces mêmes cellules mais pas des hépatocytes, suggérant que de nouvelles fonctions peuvent émerger de la plasticité conformationel de E1E2. Dans un second temps, nous sommes parvenus à identifier un dialogue conservé entre E1 et le domaine III de E2 (E2 DIII), critique pour les processus d’attachement et de fusion du VHC. Nous avons aussi montré grâce à une approche bio-informatique l’existence d’une co-évolution très importante entre E1 et E2. Cette approche a également prédit de potentiel changement de conformations au sein de l’hétérodimère, suggérant que E2 est sans doute une protéine de fusion capable de se replier sur elle-même via le repliement de son domaine III et l’aide de E1. Ainsi, ces différents travaux soulignent l’implication de E1 et E2 au sein de dialogues fins et complexes, qui régulent à la fois les conformations et les fonctions de l’hétérodimère. Ainsi, cela suggère que l’hétérodimère E1E2 représente plutôt une unité fonctionnelle et structurale unique, plutôt que l’association de deux protéines aux fonctions distinctes. / Hepatitis C Virus (HCV) infects more than 170 million people worldwide but no vaccine is available yet. HCV entry may represent a promising target for therapies and is mediated by two envelope glycoproteins, E1 and E2, assembled as heterodimer onto the virus surface. However, how E1 and E2 dialog, structurally rearrange and act together during these steps remain poorly defined. In this work, we aimed to clarify the interrelation of E1E2 during virus entry, thus opening ways to potential new therapeutic strategies. We first investigated whether a strong genetic divergence between E1E2 heterodimers may highlight distinct functions. We observed that B-cell derived E1E2 were specialized for B-cell infection, suggesting that new functions can emerge from the E1E2 conformational plasticity. In a second approach, we identified a conserved dialog between E1 and the domain III of E2 that was critical for virus binding and fusion. Moreover, a computational model predicted a strong co-evolution between E1 and E2 as well as potential structural rearrangements, suggesting that HCV E2 is likely a fusion protein able to fold over via its domain III through the mediation of E1. Altogether, these different works highlight that E1 and E2 are involved in complex dialogs that regulate the heterodimer folding and functions, suggesting that E1E2 heterodimer is more likely a single functional protein entity than an association of two proteins with specific functions.

Here we review viral and cellular requirements for entry and intracellular trafficking of foamy viruses (FVs) resulting in integration of viral sequences into the host cell genome. The virus encoded glycoprotein harbors all essential viral determinants, which are involved in absorption to the host membrane and triggering the uptake of virus particles. However, only recently light was shed on some details of FV’s interaction with its host cell receptor(s). Latest studies indicate glycosaminoglycans of cellular proteoglycans, particularly heparan sulfate, to be of utmost importance. In a species-specific manner FVs encounter endogenous machineries of the target cell, which are in some cases exploited for fusion and further egress into the cytosol. Mostly triggered by pH-dependent endocytosis, viral and cellular membranes fuse and release naked FV capsids into the cytoplasm. Intact FV capsids are then shuttled along microtubules and are found to accumulate nearby the centrosome where they can remain in a latent state for extended time periods. Depending on the host cell cycle status, FV capsids finally disassemble and, by still poorly characterized mechanisms, the preintegration complex gets access to the host cell chromatin. Host cell mitosis finally allows for viral genome integration, ultimately starting a new round of viral replication.

Les virus géants sont un groupe de virus ADN double brin caractérisés par une taille géante du virion et du génome, et un répertoire de gènes qui comprend environ 450 à 2500 gènes prédits. Une proportion importante de ces gènes (jusqu'à 93%) sont des 'ORFans', ou codent pour des protéines de fonction inconnue. Acanthamoeba polyphaga mimivirus est le premier virus géant découvert, il y a une décennie, par co-culture sur Acanthamoeba spp. Il est le membre prototype de la famille Mimiviridae. Le génome de Mimivirus code pour environ 1000 protéines, parmi lesquelles ~50% n'ont pas d'homologue connu dans les banques de séquences publiques. La capside de Mimivirus a un diamètre d'environ 500 nm et est couverte par une couche dense de fibres, à l'exception de l'un de ses sommets. Ces fibres sont d'environ 130 nm de longueur et se composent d'une tige souple et d'une tête de forme globulaire.Dans ce travail de thèse, nous avons cherché à étudier les gènes impliqués dans la formation des fibres de Mimivirus. Dans ce but, nous avons notamment exprimé des gènes candidats dans E. coli, et nous avons mis au point une stratégie qui a utilisé l'interférence ARN afin d'étudier la fonction et la structure des protéines de Mimivirus. Nous avons annoté quatre protéines associées aux fibres. La stratégie utilisant les petits ARN interférant appliquée ici est originale et a été utilisée pour la première fois pour les virus géants qui infectent les amibes. Elle pourrait permettre de décrypter la fonction des gènes des mimivirus et d'annoter potentiellement des centaines de protéines présentes dans les bases de données publiques, et de différencier l'ADN poubelle des gènes réellement utilisés. / Giant viruses are a group of double stranded DNA viruses that are characterized by a giant virion and genome size, and gene repertoires encompassing approximately 450 to 2500 predicted genes. A substantial proportion of these genes (up to 93%) consists in ORFans, or encodes proteins with unknown functions. Acanthamoeba polyphaga mimivirus is the first giant virus that was discovered, a decade ago, after co-culturing on Acanthamoeba spp. It is the prototype member of the family Mimiviridae. Mimivirus encodes about 1000 proteins, among which ~50% have no known homolog in public sequence databases. The Mimivirus capsid is about 500 nm in diameter and is covered by a dense layer of fibers, except at one of its vertices. These fibers are about 130 nm in length and consist of a soft shaft and a globular shaped head.In this thesis work, we aimed to study the genes involved in the formation of the Mimivirus fibers. For this purpose, we have expressed candidate genes in E. coli, and implemented a strategy that used RNA interference to study the function and structure of Mimivirus proteins. We then succeeded in annotating four proteins as fiber associated proteins. The short interfering RNA strategy that we applied here is original and has been used for the first time in giant viruses that infect amoeba. It could allow deciphering the function of the mimivirus gene repertoires and help annotating hundreds of proteins without known function found in public databases and differentiate between junk DNA and truly used genes.

Hepatitis C virus (HCV) represents a global health threat. HCV is a blood-borne positive-strand RNA virus belonging to the Flaviviridae family that infects ~160 million people worldwide. About 70% of infected individuals fail to clear the virus and subsequently develop chronic hepatitis, frequently leading to liver cirrhosis and in some cases hepatocellular carcinoma. Therapeutic options for HCV infection are still limited and a protective vaccine is not yet available. Currently available therapies include administration of pegylated alpha interferon in combination with ribavirin. The recently approved protease inhibitors Boceprevir and Telaprevir are also included in the treatment regimen. However, limitations to the treatment with direct-acting antivirals (DAAs) are associated with severe side effects and low sustained virological response (SVR) rates that vary depending on the virus and host genotype. The replication step of the viral life cycle is mostly targeted by majority of DAAs. Recent findings have suggested that a combination of entry inhibitors together with DAAs exhibit a synergistic effect in the treatment of HCV. Therefore, identification of efficient HCV entry inhibitors is of high priority In vitro studies have shown that HCV attachment and subsequent entry into the host cells is mediated by E1 and E2 viral envelope proteins. HCV entry requires interaction with a number of receptors which include CD81, scavenger receptor B1 (SR-B1) and the tight junction proteins, claudin 1 (CLDN1) and occludin (OCLN). Since the E2 glycoprotein is reported to interact directly with cellular receptors, it is an attractive target for neutralisation. The present study focuses on the establishment and characterisation of entry inhibitors as antivirals for HCV. The thesis is presented in three chapters: Chapter 1- ‘Introduction’, provides a brief overview on HCV genotypes, genome organisation, life cycle including details on the entry process and therapies used for the treatment of HCV. Chapter 2 describes the generation of monoclonal antibodies (mAbs) against HCV envelope proteins as potent anti-viral agents for the prevention of HCV infection. Data on the identification and characterization of the neutralizing epitopes of HCV envelope proteins have been presented. Chapter 3 includes isolation of entry inhibitors of HCV from natural sources and identification and characterization of the active components exhibiting antiviral property. A number of studies have reported the role of neutralizing antibodies in the course of HCV infection and emerging data suggest protective effect of antibodies against HCV infection. Most of the ongoing studies are based on HCV genotype 1a which is prevalent globally. However in India, the prevalent genotype is 3a. Therefore, we established a panel of mAbs against HCV-LPs comprising of core-E1-E2 derived from genotype 3a as described in chapter 2. HCV-LP based system has been used in this study since it mimics the biophysical conformation, morphology and antigenic properties of the native virion and represents a model system for studies on viral binding and entry. MAbs were characterised and analyzed for their ability to prevent viral binding and entry into host cells. Three mAbs namely E3D8, H6D3 and A10F2 were identified to recognize the E2 viral glycoprotein which significantly inhibited HCV-LP binding to Huh7 cells in vitro. The neutralizing epitopes corresponding to the mAbs were identified using overlapping truncated fragments and synthetic peptides of the E2 protein. Our experiments suggest that the epitopes recognised by the inhibitory mAbs are unique and different from those reported till now. The synergistic effect of a combination of mAbs on virus neutralization has shown promising results for treatment of viral infections. Since in the present study the epitopes recognised by the mAbs are non-overlapping, we went ahead to determine whether a combination of these mAbs would enhance the ability to block HCV-LP binding. Indeed, flow cytometry and fluorescence microscopy studies revealed that a combination of the antibodies efficiently blocked the binding of HCV-LP to human hepatoma cells. More importantly and of relevance is the observation that the mAbs in combination inhibited viral infection (JFH1 strain) and replication in permissive human hepatocytes as determined by real time RT-PCR. Phytochemicals present in plants have been considered as conducive for prevention of several viral infections and are found to be promising antiviral agents. Natural products which are biologically active disclose drug-like properties since they are small molecules and can be easily metabolised and absorbed by the body. In our study as described in chapter 3, we evaluated extracts from Indian medicinal plants and fruits which are known to have hepato-protective effect, for natural potent attachment and entry inhibitors for HCV. Flow cytometric analysis suggested that the root extract of the herb Boerhavia diffusa and fruit extract of Prunus domestica exhibited high antiviral activity by inhibiting the binding of Hepatitis C virus like particles (HCV-LPs) to the human hepatoma cells. We went on to isolate, identify and confirm the active principles to be Boeravinone H, a dehydrorotenoid, (from Boerhavia diffusa) and Rutin, a flavonoid, (from Prunus domestica) by LC-ESI-MS, NMR, UV and IR spectral analysis. Our study revealed that the compounds block the attachment as well as entry step probably by targeting the viral particle. We also assessed the efficiency of these small molecules (Boeravinone H and Rutin) to inhibit HCV negative strand synthesis post entry by real time RT-PCR. Results suggest significant inhibition of viral entry and infection in the HCV cell culture (ex vivo). To our knowledge it is the first report on Boeravinone H and Rutin as entry inhibitor for HCV. In conclusion, our findings support the potential of employing a cocktail of neutralizing mAbs and antiviral agents from natural source in the management of HCV infection.

One of the important tasks of virology and immunology is to explore the species- and cell-barriers preventing virus horizontal transmission and reveal the ways how viruses overcome these barriers and "adapt" to different species. This work is based on a well- established retroviral model - avian Rous sarcoma virus (RSV) and studies virus replication blocks in mammalian cells at both pre- and post-integration level. Interaction of the viral envelope glycoprotein (Env) with a specific cellular receptor mediates virus entry into cells. Although mammalian orthologues of specific chicken receptors do not support RSV entry, it was observed that some RSV strains are able to enter mammalian cells. Several RSV-transformed rodent cells lines were described and analysis of provirus H20- RSV in one these cells lines (hamster H-20 tumor cell line) showed multiple mutations including two crucial amino acid substitutions in different regions of Env. Substitutions D32G and L378S confer virus transmission to hamster, human and also chicken cells lacking the appropriate receptor. Altered conformation of H20-RSV Env is similar to a receptor-primed (activated) state of Env. This observation indicates that virus can circumvent the need of original cell receptor because of spontaneous Env activation caused by single...